MediciNova Receives Notice of Patent Allowance for Method of Treating Acute Exacerbations of Asthma

MediciNova Receives Notice of Patent Allowance for Method of Treating Acute
Exacerbations of Asthma

SAN DIEGO, Dec. 9, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a
biopharmaceutical company that is publicly traded on the NASDAQ Global Market
(Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code
Number: 4875), announced that it has been granted a Notice of Allowance from
the U.S. Patent and Trademark Office for a pending patent application, which
covers the use of MN-221 for the treatment of acute exacerbations of asthma.

The MN-221 patent maturing from this allowed patent application is expected to
expire no earlier than 2030 and includes claims covering the use of MN-221
(bedoradrine) in combination with a standard of care (SOC) treatment regimen.
The allowed claims include specific coverage for different routes of
administration, including intravenous, oral and inhalation. SOC may include
agents such as a beta-agonist bronchodilator or anti-cholinergic or
corticosteroid or combinations thereof.

About MediciNova

MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon
acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet need with a commercial focus on the U.S. market.
Through strategic alliances primarily with Japanese pharmaceutical companies,
MediciNova holds rights to a diversified portfolio of clinical and preclinical
product candidates, each of which MediciNova believes has a well-characterized
and differentiated therapeutic profile, attractive commercial potential, and
patent coverage of commercially adequate scope.MediciNova's current strategy
is to focus on its two prioritized product candidates, MN-166 (ibudilast) for
neurological disorders, and MN-221 for the treatment of acute exacerbations of
asthma and chronic obstructive pulmonary disease exacerbations.MN-166 is
being developed in Phase 1 and Phase 2 clinical trials for pain and drug
addiction, largely through Investigator INDs and outside funding.
Proof-of-concept Phase 2b trial(s) in Progressive MS are pending. MediciNova
is engaged in strategic partnering and consortium funding discussions to
support further development of both the MN-221 and ibudilast/MN-166 programs.
For more information on MediciNova, Inc., please visit

The MediciNova, Inc. logo is available at

Statements in this press release that are not historical in nature constitute
forward-looking statements within the meaning of the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, without limitation, statements regarding our clinical
development strategies, including future development, statements regarding the
progress of clinical trials, statements regarding expectations for the
ibudilast/MN-166 program, including development of ibudilast/MN-166 for
certain indications and expectations on future progress in the development of
our drug candidates, expected timing of clinical trial results and any
implication as to the results of our development, partnering and funding
efforts or that the company will have the ability to execute on its
priorities. These forward-looking statements may be preceded by, followed by
or otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will," "would," or
similar expressions. These forward-looking statements involve a number of
risks and uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking statements.
Factors that may cause actual results or events to differ materially from
those expressed or implied by these forward-looking statements, include, but
are not limited to, risks and uncertainties inherent in clinical trials,
including the potential cost, expected timing and risks associated with
clinical trials designed to meet FDA guidance and the viability of further
development considering these factors, product development and
commercialization risks, the uncertainty of whether the results of clinical
trials will be predictive of results in later stages of product development,
the risk of delays or failure to obtain or maintain regulatory approval, risks
associated with the reliance on third parties to sponsor and fund clinical
trials, risks regarding intellectual property rights in product candidates and
the ability to defend and enforce such intellectual property rights, the risk
of failure of the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform as expected,
the risk of increased cost and delays due to delays in the commencement,
enrollment, completion or analysis of clinical trials or significant issues
regarding the adequacy of clinical trial designs or the execution of clinical
trials, and the timing of expected filings with the regulatory authorities,
MediciNova's collaborations with third parties, the availability of funds to
complete product development plans and MediciNova's ability to raise
sufficient capital when needed, and the other risks and uncertainties
described in MediciNova's filings with the Securities and Exchange Commission,
including its annual report on Form 10-K for the year ended December 31, 2011
and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance
should not be placed on these forward-looking statements, which speak only as
of the date hereof. MediciNova disclaims any intent or obligation to revise or
update these forward-looking statements.

         Mark Johnson
         Investor Relations
         MediciNova, Inc.
         (858) 373-1300
         Stephanie Ashe
         Continuum Health Communications

MediciNova, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.